Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A029: Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients

Fernando T. Kreutz
Fernando T. Kreutz
FKx Inc, Toronto, ON, Canada.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A029 Published January 2016
  • Article
  • Info & Metrics
Loading
Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY

Abstract

We described a non-randomized control phase II trial, using a novel Cell Based Cancer Immunotherapy using Tumor Presenting Cells (TPC). The patient population was selected at HCPA – Porto Alegre Brazil (University Hospital). Patients with clinical localized prostate cancer and scheduled to undergo radical retro pubic prostatectomy (RRP) were identified. High-risk patients (initial PSA levels above 10 ng/ml, Gleason above 8 or upstaged from the clinical staging) were offer to participate on the trial. This group of patients represent a very important clinical population that cloud benefit from an adjuvant therapy. Tumor Presenting Cells are a new strategy for immunotherapy. Solid tumor cells as other non-immunological cells do not present MHC Class II. The MHC class II is a critical molecule responsible for peptide presentation to T helper cells. The presence of a not-self peptide on a MHC II molecule trigger the production of cytokines responsible for different steps on T cell expansion and maturation. Without the appropriate cytokine stimulation, cytotoxic T cells that identified a not-self peptide associate to a MHC class I molecules, may not proliferate or even be induce to anergy. In our model, solid tumor cells (prostate cancer) are induce to express MHCII on their surface. In this novel approach of Cell Based Cancer Immunotherapy (CBCI), patient's tumor cells were expanded in tissue culture and treated causing de novo expression of MHC II and activation of the MHC II peptide presentation pathway. Thus, the modified cancer cells are bifunctional, being capable of activating both helper T cells (MHC II) and cytotoxic T cells (MHCI), leading to cytokine production and a surprisingly robust and cancer-specific immune response. The modified solid tumor cell by itself will now behave as an antigen-presenting cell creating a Tumor Presenting Cell (TPC). Once the tumor cells are modified, they are irradiated and inoculated as intradermal injections (7 doses). Although the individualized preparation of CBCI is labor intensive, we were able to prepare the cell material on almost all collected samples (103/107 - 96%). DTH reactions (≥ 5 mm) were positive in 73% of the patients (16/23). This study corroborates with low toxicity of cell based immunotherapy. We have found mild skin reactions on inoculation sites in all vaccinated patients. More intense reactions (ulceration, low-grade fever, and adenopathy) were found in 13% of patients (3/23). We demonstrated a clinical benefit with the used of the CBCI: 27% (6/22) of the patients submitted to CBCI presented detectable levels of PSA (above 0.004 ng/mL) after 5 years, when compare to 53% (19/36) on the control group (p=0.03). There was also trend on reduction of cancer related mortality, 4% (1/23) on the CBCI group against 10% (4/40) on the control group. Several new therapies were approved in recent years for advanced prostate cancer treatment. The pharmaco-economic cost of these therapies are significant, and most of them shown an improvement survival of less than six months. New therapies such as Cell Base Cancer Immunotherapy with Tumor Presenting Cells could change this scenario, improving quality life, reducing mortality and cost to the health care providers. We are now designing a Phase III trial in North America for local advance prostate cancer. Other indication (triple negative breast cancer, pancreatic or gastric cancer patients) are also under evaluation.

Citation Format: Fernando T. Kreutz. Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A029.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 4 (1 Supplement)
January 2016
Volume 4, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A029: Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A029: Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients
Fernando T. Kreutz
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A029; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A029

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A029: Cell-based cancer immunotherapy using tumor presenting cells: A phase II trial with local advance prostate cancer patients
Fernando T. Kreutz
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A029; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A029
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement